Season 2 (2021-2030)

Oncology - Preclinical (37)

Modality Indication Targets Stage Company Project No. Detail
1 Non.clinical development of C2.558, a SOS1 inhibitor, for the treatment of patients with KRAS mutant solid tumors
Small Molecules Solid tumor KRAS.SOS1 PPI Preclinical Cyrus Therapeutics Inc. RS-2023-00283208
2 Non.clinical development of CYRS1542, a GSPT1 Molecular Glue Degrader, for the treatment of patients with SCLC and AML
Small Molecules SCLC, AML GSPT1 Preclinical Cyrus Therapeutics Inc. RS-2023-00282972
3 Preclinical Development of Anti.FGFR3 ADC for the Treatment of Bladder Cancer and Brain Tumor
Antibody Glioblastoma FGFR3 Preclinical Aimedbio RS-2023-00282706
4 Development of HLA.G CAR.T cell therapy targeting HLA.G.positive solid tumors
Gene Therapy Solid tumor HLA.G Preclinical HK Inno. N RS-2023-00282541
5 Preclinical development of a MET degrader as a novel NSCLC agent
Small Molecules NSCLC MET (a receptor tyrosine kinase) Preclinical InnoCure Therapeutics RS-2023-00259138
6 Nonclinical development of AR degrader UBX.103335 for the treatment of metastatic castration.resistant prostate cancer
Small Molecules Castration.resistant prostate cancer Androgen receptor (AR) Preclinical Ubix Therapeutics RS-2023-00258142
7 Preclinical study of CLDN18.2 targeting antibody-drug conjugate for gastric cancer treatment
Drug-conjugate Gastric cancer, Gastroesophageal junction edema cancer CLDN18.2 Preclinical AbTis Co., Ltd. RS-2023-00219493
8 Pre-clinical development of SCB0020160, a Sirt6 agonist with a potent anti-cancer effect
Small Molecules pancreatic cancer SIRT6 Preclinical SCBIO RS-2023-00218894
9 Non-clinical studies of VRN101099, a brain permeable HER2 selective kinase inhibitor
Small Molecules Breast cancer, Colon cancer HER2 Preclinical VORONOI RS-2023-00217541
10 Non-clinical study of NRT-YHD-001 as macrophage immune check point blocker in liver cancer
Gene Therapy Liver cancer let-7i-5p miRNA Preclinical NEORNAT Inc. RS-2023-00217374
11 Pre-clinical development of anticancer candidate to treat small cell lungcancer (SCLC) through PROTAC-based PLK1 protein degradation
Small Molecules NSCLC PLK1 Preclinical UPPPTHERA RS-2022-00167113
12 Non-clinical study and IND approval of GI-108, a metabolic immune anti-cancer drug
Recombinant Protein Solid Tumor CD73, IL-2 Preclinical GI Innovation, Inc RS-2022-00166700
13 Non-clinical Development of SREBP1 Degrader for the Cancer Stem Cell-targeted Treatment of Glioblastoma
Small Molecules Glioblastoma SCAP:SREBP1 Preclinical MEDIFIC RS-2022-00166323
14 IND approval and securing IMP batch for GENA-104A16, an immune checkpoint inhibitor targeting CNTN4
Antibody Solid Tumor CNTN4 Preclinical Genome&Company RS-2022-00166157
15 Non-clinical study on the development of customized targeted anticancer agent for the treatment of advanced Hepatocellular Carcinoma
Small Molecules Liver cancer FLT3/VEGFR2/PDGFRb TK Preclinical Etnova Therapeutics RS-2022-00165725
16 Preclinical study for the development of MRI contrast agent of innovative artificial melanin
Others Diagnostic Liver, Kidney Preclinical BL Melanis RS-2022-00165594
17 Non-clinical development of long-acting IL-2 analog (HM16390) with optimized IL-2 receptor binding property
Recombinant Protein Renal cell carcinoma, melanoma IL-2 Preclinical Hanmi Pharm. Co., Ltd. RS-2022-00165557
18 An Oral, Selective, and Potent EGFR Mutant Protein Degrader for the Treatment of NSCLC
Small Molecules NSCLC(EGFR mutation) EGFR Preclinical J2H Biotech HN22C0670
19 Non-clinical study of VRN11, a CNS-penetrable inhibitor for EGFR
G719X, L861X, S768I/V as well as C797S mutation NSCLC patients
Small Molecules NSCLC(EGFR mutation) EGFR Preclinical Voronoi, Inc HN22C0663
20 Preclinical study of DA-4505 for the treatment of cancer immunotherapy
Small Molecules Advanced Solid Tumor AhR Preclinical DONG-A ST HN22C0630
21 JW2286, a novel inhibitor directly targeting of STAT3, drug discovery for solid cancer including triple negative cancer
Small Molecules TNBC STAT3 Preclinical JW Pharmaceutical HN22C0583
22 ENPP1 Inhibitor TXN10128
Small Molecules Colorectal cancer ENPP1 Preclinical TXINNO Bioscience Inc HN22C0531
23 Preclinical development of ITC-6146RO, a B7-H3 targeting ADC, for the Treatment of Non-Small Cell Lung Cancer
Drug-conjugate NSCLC B7-H3 Preclinical IntoCell HN22C0373
24 Development of gene therapy for NMIBC using bispecific RNAi
Gene Therapy Bladder Cancer, Head And Neck Cancer, Pancreatic Cancer mTOR, STAT3 Preclinical Curigin HN22C0365
25 Preclinical Development of LEM-S403 Targeting Tumor Microenvironment Immune Modulation of Immune Checkpoint Inhibitor Non-Responsive Solid Tumor
Gene Therapy Solid Tumor IDO1 Preclinical Lemonex Inc. HN22C0262
26 Development of L1CAM targeted CAR-T therapy for recurrent ovarian cancer
Gene Therapy Ovarian Cancer L1CAM Preclinical Cartexell Inc HN22C0250
27 Development of a first-in-class immunotherapy for treatment of non-small cell lung cancer with PD-L1 negative/low
Antibody Lung Cancer IGSF1 Preclinical Wellmarkerbio HN22C0157
28 Nonclinical study of the immuno-oncological therapeutic antibody against novel immune checkpoint CD300c
Antibody Lung cancer, Colorectal, Breast cancer CD300c Preclinical CentricsBio Inc. HN21C1400
29 Preclinical study of IOH-001, a Bispecific Antibody immunotherapy targeting PD-L1 and CD47
Antibody TNBC PD-L1, CD47 Preclinical ImmuneOncia HN21C1388
30 Production of non-clinical and clinical samples of TROP2-ADC for IND filing and approval, or technology transfer
Drug-conjugate Solid Tumor TROP2 Preclinical LegoChem Biosciences, Inc. HN21C1199
31 Non-clinical development of HM97662, an epigenetic protein EZH1/2 dual inhibitor, as a treatment for various cancers
Small Molecules Malignant tumor EZH1/2 Preclinical Hanmi Pharm. Co., Ltd. HN21C1077
32 Pre-clinical Studies and IND Approval of First-in-class Cancer Stemness Blocking Anti-Cancer Agent, PMB212
Small Molecules Resistant cancer PIN1 Preclinical PimedBio HN21C0955
33 Preclinical study of JPC-089, a blood cancer treatment targeting PIM kinase
Small Molecules AML PIM Kinase Preclinical Jeil Pharmaceutical CO.,LTD. HN21C0886
34 NN3201, an IND-enabling study stage multimodal, cKIT-targeting ADC for SCLC, GIST, and AML
Drug-conjugate Gastrointestinal stromal tumor C-kit, microtuble inhibition에 의한 cell cycle arrest, apoptosis 유도 Preclinical Novelty Nobility Inc. HN21C0860
35 Development of anti-VISTA antibody PMC-309 for the treatment of NSCLC
Antibody NSCLC VISTA Preclinical PharmAbcine Inc. HN21C0774
36 ABL103, A novel T-cell engaging bispecific antibody, exhibits potent in vitro and vivo antitumor activity and low toxicity via B7-H4 dependent 4-1BB activation in tumor microenvironment
Antibody Solid Tumor B7-H4, 4-1BB Preclinical ABLBio HN21C0614
37 Non-clinical study of VRN08, an oral Mps1 inhibitor to modulate SAC for advanced solid tumor
Small Molecules TNBC and CDK4/6i resistant solid tumors Mps1 Preclinical Voronoi Inc. HN21C0580
BACK